1245916-14-6
1245916-14-6 structure
- Name: Alirocumab
- Chemical Name: Alirocumab
- CAS Number: 1245916-14-6
- Molecular Formula: C6472H9996N1736O2032S42
- Molecular Weight:
- Catalog: Signaling Pathways Metabolic Enzyme/Protease Ser/Thr Protease
- Create Date: 2018-06-29 01:45:22
- Modify Date: 2024-01-14 19:26:09
-
Alirocumab (REGN 727) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia[1].
| Name | Alirocumab |
|---|---|
| Synonyms | ALIROCUMAB |
| Description | Alirocumab (REGN 727) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705. |
| Molecular Formula | C6472H9996N1736O2032S42 |
|---|